Category: Pα+ - Page 7 - Psychedelic Alpha

Read more about the article Breaking: Lykos Lays Off 75% of Staff, Ropes In Pharma Veteran, Doblin Resigns Board

Breaking: Lykos Lays Off 75% of Staff, Ropes In Pharma Veteran, Doblin Resigns Board

Post published:August 15, 2024
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #170: Is MindMed Eyeing Depression? atai Approaches Phase 2 for DMT and R-MDMA Candidates; Compass’ Phase 3 Readout Timeline; European Psychiatrists Remain Open to Psychedelics

Pα+ Psychedelic Bulletin #170: Is MindMed Eyeing Depression? atai Approaches Phase 2 for DMT and R-MDMA Candidates; Compass’ Phase 3 Readout Timeline; European Psychiatrists Remain Open to Psychedelics

Post published:August 15, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Lykos Plots FDA Appeal: Reeling from CRL and Journal Article Retractions, MDMA Developer Hopes to Change Your Mind

Lykos Plots FDA Appeal: Reeling from CRL and Journal Article Retractions, MDMA Developer Hopes to Change Your Mind

Post published:August 13, 2024
Post category:Analysis News Pα+

Read more about the article Psychedelic Funding Update: Q2 2024

Psychedelic Funding Update: Q2 2024

Post published:August 1, 2024
Post category:Analysis Pα+

Read more about the article Pα+ Psychedelic Bulletin #169: Brin Backs Soneira, But Patent Questions Loom Large; J&J Seeks Spravato Monotherapy Approval; Canadian Study to Parse Out Role of Psychotherapy

Pα+ Psychedelic Bulletin #169: Brin Backs Soneira, But Patent Questions Loom Large; J&J Seeks Spravato Monotherapy Approval; Canadian Study to Parse Out Role of Psychotherapy

Post published:July 26, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #168: California’s Psychedelic Research Bottleneck Ends Today; Neşe Devenot’s Letter to the Editor; Oregon’s Psilocybin Services a Year In; Disability and Psychedelics

Pα+ Psychedelic Bulletin #168: California’s Psychedelic Research Bottleneck Ends Today; Neşe Devenot’s Letter to the Editor; Oregon’s Psilocybin Services a Year In; Disability and Psychedelics

Post published:July 19, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Regulation Beyond Prohibition: RAND Corporation Delivers Report on US Psychedelic Policymaking

Regulation Beyond Prohibition: RAND Corporation Delivers Report on US Psychedelic Policymaking

Post published:July 16, 2024
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #167: Lykos Insiders, Affiliates Respond to Critics; FDA-Affiliated Workshop Discusses Ketamine; EMA Associates Publish Recap of Psychedelics Workshop

Pα+ Psychedelic Bulletin #167: Lykos Insiders, Affiliates Respond to Critics; FDA-Affiliated Workshop Discusses Ketamine; EMA Associates Publish Recap of Psychedelics Workshop

Post published:July 12, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Dutch Committee Seeks to Expedite MDMA-Assisted Therapy for PTSD

Dutch Committee Seeks to Expedite MDMA-Assisted Therapy for PTSD

Post published:July 9, 2024
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #166: Crenshaw and Musk Weigh In on MDMA; Drug Devs Clarify Trial Design In Wake of AdComm; Mini Interview: Joshua Ismin, Psylo

Pα+ Psychedelic Bulletin #166: Crenshaw and Musk Weigh In on MDMA; Drug Devs Clarify Trial Design In Wake of AdComm; Mini Interview: Joshua Ismin, Psylo

Post published:July 5, 2024
Post category:Psychedelic Bulletin Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.